C609T polymorphism of NADPH quinone oxidoreductase 1 correlates clinical hematological toxicities in lung cancer patients treated with amrubicin

Clinical Medicine Insights: Oncology

Volumn 7, Issue , 2012, Pages 31-39

  Nagata, Misato ^a   Kimura, Tatsuo ^a   Suzumura, Tomohiro ^a   Kira, Yukimi ^a   Nakai, Toshiyuki ^a   Umekawa, Kanako ^a   Tanaka, Hidenori ^a   Matsuura, Kuniomi ^a   Mitsuoka, Shigeki ^a   Yoshimura, Naruo ^a   Oka, Takako ^a   Kudoh, Shinzoh ^a   Hirata, Kazuto ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Amrubicin; Hematological toxicity; Lung cancer; NQO1; SNP

Indexed keywords

AMRUBICIN; CYSTEINE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); THREONINE;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BLOOD SAMPLING; BLOOD TOXICITY; CARDIOTOXICITY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG DETERMINATION; FEBRILE NEUTROPENIA; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; LEUKOPENIA; LUNG CANCER; MALE; MUTATOR GENE; NADPH QUINONE OXIDOREDUCTASE 1 GENE; NEUTROPENIA; PHARMACODYNAMICS; PHARMACOGENOMICS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 84874219564     PISSN: 11795549     EISSN: None     Source Type: Journal    
DOI: 10.4137/CMO.S10839     Document Type: Article

References (33)

1. Batist G, Carney DN, Cowan KH, et al. Etoposide (VP-16) and cisplatin in previously treated small-cell lung cancer: clinical trial and in vitro correlates. J Clin Oncol. 1986;4(6):982-6.
2. Weiss RB, Sarosy G, Clagett-Carr K, Russo M, Leyland-Jones B. Anthracycline analogs: the past, present, and future. Cancer Chemother Pharmacol. 1986;18(3):185-97.
3. Yana T, Negoro S, Takada M, et al. Phase II study of amrubicin in previously untreated patients with extensive-disease small cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) study. Invest New Drugs. 2007;25(3):253-8.
4. Takeda K, Takifuji N, Negoro S, et al. Phase II study of amrubicin, 9-aminoanthracycline, in patients with advanced non-small-cell lung cancer: a West Japan Thoracic Oncology Group (WJTOG) study. Invest New Drugs. 2007;25(4):377-83.
5. Inoue A, Sugawara S, Yamazaki K, et al. Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402. J Clin Oncol. 2008;26(33):5401-6.
6. Ettinger DS, Jotte R, Lorigan P, et al. Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer. J Clin Oncol. 2010;28(15):2598-603.
7. Kaneda H, Okamoto I, Hayashi H, et al. Phase II trial of amrubicin for second-line treatment of advanced non-small cell lung cancer: results of the West Japan Thoracic Oncology Group trial (WJTOG0401). J Thorac Oncol. 2010;5(1):105-9.
8. Mitsuoka S, Kudoh S, Kimura T, et al. Clinical outcome of amrubicin therapy according to the prior chemotherapy sensitivities of extensive small cell lung cancer. Osaka City Med J. 2011;57(2):59-66.
9. Onoda S, Masuda N, Seto T, et al. Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301. J Clin Oncol. 2006;24(34):5448-53.
10. Ohe Y, Negoro S, Matsui K, et al. Phase I-II study of amrubicin and cisplatin in previously untreated patients with extensive-stage small-cell lung cancer. Ann Oncol. 2005;16(3):430-6.
11. Ross D, Siegel D. NAD(P)H: quinone oxidoreductase 1 (NQO1, DT-diaphorase), functions and pharmacogenetics. Methods Enzymol. 2004;382: 115-44.
12. Ross D, Kepa JK, Winski SL, Beall HD, Anwar A, Siegel D. NAD(P)H:quinone oxidoreductase 1 (NQO1): chemoprotection, bioactivation, gene regulation and genetic polymorphisms. Chem Biol Interact. 2000;129(1-2): 77-97.
13. Spanswick VJ, Cummings J, Smyth JF. Current issues in the enzymology of mitomycin C metabolic activation. Gen Pharmacol. 1998;31(4):539-44.
14. Ross D, Siegel D, Beall H, Prakash AS, Mulcahy RT, Gibson NW. DT-diaphorase in activation and detoxification of quinones. Bioreductive activation of mitomycin C. Cancer Metastasis Rev. 1993;12(2):83-101.
15. Taatjes DJ, Fenick DJ, Gaudiano G, Koch TH. A redox pathway leading to the alkylation of nucleic acids by doxorubicin and related anthracyclines: application to the design of antitumor drugs for resistant cancer. Curr Pharm Des. 1998;4(3):203-18.
16. Tani N, Yabuki M, Komuro S, Kanamaru H. Characterization of the enzymes involved in the in vitro metabolism of amrubicin hydrochloride. Xenobiotica. 2005;35(12):1121-33.
17. Salvatorelli E, Menna P, Gonzalez Paz O, et al. Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model. II. Amrubicin shows metabolic advantages over doxorubicin and epirubicin. J Pharmacol Exp Ther. 2012;341(2):474-83.
18. Traver RD, Horikoshi T, Danenberg KD, et al. NAD(P)H:quinone oxidoreductase gene expression in human colon carcinoma cells: characterization of a mutation which modulates DT-diaphorase activity and mitomycin sensitivity. Cancer Res. 1992;52(4):797-802.
19. Fagerholm R, Hofstetter B, Tommiska J, et al. NAD(P) H:quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer. Nat Genet. 2008;40(7):844-53.
20. Lawson KA, Woodson K, Virtamo J, Albanes D. Association of the NAD(P)H: quinone oxidoreductase (NQO1) 609C-.T polymorphism with lung cancer risk among male smokers. Cancer Epidemiol Biomarkers Prev. 2005;14(9):2275-6.
21. Chao C, Zhang ZF, Berthiller J, Boffetta P, Hashibe M. NAD(P)H: quinone oxidoreductase 1 (NQO1) Pro187Ser polymorphism and the risk of lung, bladder, and colorectal cancers: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2006;15(5):979-87.
22. Kelsey KT, Ross D, Traver RD, et al. Ethnic variation in the prevalence of a common NAD(P)H quinone oxidoreductase polymorphism and its implications for anti-cancer chemotherapy. Br J Cancer. 1997;76(7): 852-4.
23. Siegel D, Anwar A, Winski SL, Kepa JK, Zolman KL, Ross D. Rapid polyubiquitination and proteasomal degradation of a mutant form of NAD(P)H: quinone oxidoreductase 1. Mol Pharmacol. 2001;59(2):263-8.
24. Yoshimura N, Kimura T, Mitsuoka S, et al. Dose Escalation and Feasibility Study of Amrubicin Combined With Cisplatin in Previously Untreated Patients With Advanced Non-small-cell Lung Cancer. Am J Clin Oncol. Jan 19, 2012. [Epub ahead of print.]
25. Noguchi T, Ichii S, Morisada S, Yamaoka T, Yanagi Y. Tumor-selective distribution of an active metabolite of the 9-aminoanthracycline amrubicin. Jpn J Cancer Res. 1998;89(10):1061-6.
26. Einhorn LH, Williams SD. The role of cis-platinum in solid-tumor therapy. N Engl J Med. 1979;300(6):289-91.
27. Johnsson A, Hoglund P, Grubb A, Cavallin-Stahl E. Cisplatin pharmacokinetics and pharmacodynamics in patients with squamous-cell carcinoma of the head/neck or esophagus. Cancer Chemother Pharmacol. 1996;39(1-2): 25-33.
28. Minami H, Ohe Y, Niho S, et al. Comparison of pharmacokinetics and pharmacodynamics of docetaxel and Cisplatin in elderly and non-elderly patients: why is toxicity increased in elderly patients? J Clin Oncol. 2004; 22(14):2901-8.
29. Krajinovic M, Labuda D, Mathonnet G, et al. Polymorphisms in genes encoding drugs and xenobiotic metabolizing enzymes, DNA repair enzymes, and response to treatment of childhood acute lymphoblastic leukemia. Clin Cancer Res. 2002;8(3):802-10.
30. Kolesar JM, Pritchard SC, Kerr KM, Kim K, Nicolson MC, McLeod H. Evaluation of NQO1 gene expression and variant allele in human NSCLC tumors and matched normal lung tissue. Int J Oncol. 2002;21(5): 1119-24.
31. Fleming RA, Drees J, Loggie BW, et al. Clinical significance of a NAD(P)H: quinone oxidoreductase 1 polymorphism in patients with disseminated peritoneal cancer receiving intraperitoneal hyperthermic chemotherapy with mitomycin C. Pharmacogenetics. 2002;12(1):31-7.
32. Takakuwa O, Oguri T, Ozasa H, et al. C609T polymorphism of NAD(P)H quinone oxidoreductase 1 as a predictive biomarker for response to amrubicin. J Thorac Oncol. 2011;6(11):1826-32.
33. Kimura T, Kudoh S, Mitsuoka S, et al. Plasma concentration of amrubicinol in plateau phase in patients treated for 3 days with amrubicin is correlated with hematological toxicities. Anticancer Drugs. 2009;20(6):513-8.